Equities research analysts expect that Zymeworks Inc. (NYSE:ZYME – Get Rating) will report earnings of ($0.86) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Zymeworks’ earnings, with estimates ranging from ($1.00) to ($0.79). Zymeworks posted earnings of ($1.31) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 34.4%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Zymeworks will report full year earnings of ($3.76) per share for the current financial year, with EPS estimates ranging from ($4.65) to ($3.08). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.85) per share, with EPS estimates ranging from ($3.08) to $0.46. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Zymeworks.
Zymeworks (NYSE:ZYME – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. The firm had revenue of $19.87 million for the quarter, compared to the consensus estimate of $12.69 million. Zymeworks had a negative net margin of 858.18% and a negative return on equity of 84.77%.
ZYME traded up $0.34 during mid-day trading on Friday, reaching $5.55. 1,147,289 shares of the stock were exchanged, compared to its average volume of 3,387,387. The stock has a market capitalization of $320.62 million, a PE ratio of -1.18 and a beta of 1.06. The company has a 50 day moving average price of $6.30 and a two-hundred day moving average price of $11.68. Zymeworks has a 1 year low of $4.56 and a 1 year high of $39.41.
Several institutional investors and hedge funds have recently made changes to their positions in ZYME. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Zymeworks during the first quarter valued at about $31,000. Compagnie Lombard Odier SCmA grew its holdings in shares of Zymeworks by 233.3% during the first quarter. Compagnie Lombard Odier SCmA now owns 10,000 shares of the company’s stock worth $66,000 after purchasing an additional 7,000 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Zymeworks in the first quarter worth approximately $66,000. Teacher Retirement System of Texas purchased a new stake in Zymeworks in the first quarter worth approximately $67,000. Finally, Prospera Financial Services Inc purchased a new stake in Zymeworks in the first quarter worth approximately $72,000. Hedge funds and other institutional investors own 68.38% of the company’s stock.
Zymeworks Company Profile (Get Rating)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
- Get a free copy of the StockNews.com research report on Zymeworks (ZYME)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.